The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.
<h4>Background</h4>In India as elsewhere, multi-drug resistance (MDR) poses a serious challenge in the control of tuberculosis (TB). The End TB strategy, recently approved by the world health assembly, aims to reduce TB deaths by 95% and new cases by 90% between 2015 and 2035. A key pill...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0131438 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161548512722944 |
|---|---|
| author | Kuldeep Singh Sachdeva Neeraj Raizada Radhey Shyam Gupta Sreenivas Achuthan Nair Claudia Denkinger Chinnambedu Nainarappan Paramasivan Shubhangi Kulsange Rahul Thakur Puneet Dewan Catharina Boehme Nimalan Arinaminpathy |
| author_facet | Kuldeep Singh Sachdeva Neeraj Raizada Radhey Shyam Gupta Sreenivas Achuthan Nair Claudia Denkinger Chinnambedu Nainarappan Paramasivan Shubhangi Kulsange Rahul Thakur Puneet Dewan Catharina Boehme Nimalan Arinaminpathy |
| author_sort | Kuldeep Singh Sachdeva |
| collection | DOAJ |
| description | <h4>Background</h4>In India as elsewhere, multi-drug resistance (MDR) poses a serious challenge in the control of tuberculosis (TB). The End TB strategy, recently approved by the world health assembly, aims to reduce TB deaths by 95% and new cases by 90% between 2015 and 2035. A key pillar of this approach is early diagnosis of tuberculosis, including use of higher-sensitivity diagnostic testing and universal rapid drug susceptibility testing (DST). Despite limitations of current laboratory assays, universal access to rapid DST could become more feasible with the advent of new and emerging technologies. Here we use a mathematical model of TB transmission, calibrated to the TB epidemic in India, to explore the potential impact of a major national scale-up of rapid DST. To inform key parameters in a clinical setting, we take GeneXpert as an example of a technology that could enable such scale-up. We draw from a recent multi-centric demonstration study conducted in India that involved upfront Xpert MTB/RIF testing of all TB suspects.<h4>Results</h4>We find that widespread, public-sector deployment of high-sensitivity diagnostic testing and universal DST appropriately linked with treatment could substantially impact MDR-TB in India. Achieving 75% access over 3 years amongst all cases being diagnosed for TB in the public sector alone could avert over 180,000 cases of MDR-TB (95% CI 44187 - 317077 cases) between 2015 and 2025. Sufficiently wide deployment of Xpert could, moreover, turn an increasing MDR epidemic into a diminishing one. Synergistic effects were observed with assumptions of simultaneously improving MDR-TB treatment outcomes. Our results illustrate the potential impact of new and emerging technologies that enable widespread, timely DST, and the important effect that universal rapid DST in the public sector can have on the MDR-TB epidemic in India. |
| format | Article |
| id | doaj-art-5b6388a241e54f0fa6f5f46a30e0e0e9 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5b6388a241e54f0fa6f5f46a30e0e0e92025-08-20T02:22:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01107e013143810.1371/journal.pone.0131438The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis.Kuldeep Singh SachdevaNeeraj RaizadaRadhey Shyam GuptaSreenivas Achuthan NairClaudia DenkingerChinnambedu Nainarappan ParamasivanShubhangi KulsangeRahul ThakurPuneet DewanCatharina BoehmeNimalan Arinaminpathy<h4>Background</h4>In India as elsewhere, multi-drug resistance (MDR) poses a serious challenge in the control of tuberculosis (TB). The End TB strategy, recently approved by the world health assembly, aims to reduce TB deaths by 95% and new cases by 90% between 2015 and 2035. A key pillar of this approach is early diagnosis of tuberculosis, including use of higher-sensitivity diagnostic testing and universal rapid drug susceptibility testing (DST). Despite limitations of current laboratory assays, universal access to rapid DST could become more feasible with the advent of new and emerging technologies. Here we use a mathematical model of TB transmission, calibrated to the TB epidemic in India, to explore the potential impact of a major national scale-up of rapid DST. To inform key parameters in a clinical setting, we take GeneXpert as an example of a technology that could enable such scale-up. We draw from a recent multi-centric demonstration study conducted in India that involved upfront Xpert MTB/RIF testing of all TB suspects.<h4>Results</h4>We find that widespread, public-sector deployment of high-sensitivity diagnostic testing and universal DST appropriately linked with treatment could substantially impact MDR-TB in India. Achieving 75% access over 3 years amongst all cases being diagnosed for TB in the public sector alone could avert over 180,000 cases of MDR-TB (95% CI 44187 - 317077 cases) between 2015 and 2025. Sufficiently wide deployment of Xpert could, moreover, turn an increasing MDR epidemic into a diminishing one. Synergistic effects were observed with assumptions of simultaneously improving MDR-TB treatment outcomes. Our results illustrate the potential impact of new and emerging technologies that enable widespread, timely DST, and the important effect that universal rapid DST in the public sector can have on the MDR-TB epidemic in India.https://doi.org/10.1371/journal.pone.0131438 |
| spellingShingle | Kuldeep Singh Sachdeva Neeraj Raizada Radhey Shyam Gupta Sreenivas Achuthan Nair Claudia Denkinger Chinnambedu Nainarappan Paramasivan Shubhangi Kulsange Rahul Thakur Puneet Dewan Catharina Boehme Nimalan Arinaminpathy The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. PLoS ONE |
| title | The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. |
| title_full | The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. |
| title_fullStr | The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. |
| title_full_unstemmed | The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. |
| title_short | The Potential Impact of Up-Front Drug Sensitivity Testing on India's Epidemic of Multi-Drug Resistant Tuberculosis. |
| title_sort | potential impact of up front drug sensitivity testing on india s epidemic of multi drug resistant tuberculosis |
| url | https://doi.org/10.1371/journal.pone.0131438 |
| work_keys_str_mv | AT kuldeepsinghsachdeva thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT neerajraizada thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT radheyshyamgupta thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT sreenivasachuthannair thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT claudiadenkinger thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT chinnambedunainarappanparamasivan thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT shubhangikulsange thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT rahulthakur thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT puneetdewan thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT catharinaboehme thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT nimalanarinaminpathy thepotentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT kuldeepsinghsachdeva potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT neerajraizada potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT radheyshyamgupta potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT sreenivasachuthannair potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT claudiadenkinger potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT chinnambedunainarappanparamasivan potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT shubhangikulsange potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT rahulthakur potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT puneetdewan potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT catharinaboehme potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis AT nimalanarinaminpathy potentialimpactofupfrontdrugsensitivitytestingonindiasepidemicofmultidrugresistanttuberculosis |